CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2014 - 2026)

CytomX Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 49.47% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $35.0 million (down 49.47% YoY), and the FY2025 full-year result was $48.2 million, down 58.75% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $35.0 million, down from $48.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $346.6 million in Q4 2022, with the low at $35.0 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $171.0 million across 5 years, with a median of $172.4 million in 2024.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slipped 6.56% — and 2025, when it slumped 72.7%.
• CytomX Therapeutics' Total Non-Current Liabilities stood at $346.6 million in 2022, then retreated by 29.22% to $245.3 million in 2023, then plunged by 52.36% to $116.9 million in 2024, then tumbled by 58.75% to $48.2 million in 2025, then retreated by 27.39% to $35.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $35.0 million (Q1 2026), $48.2 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.